home / stock / bntc / bntc quote
Last: | $9.49 |
---|---|
Change Percent: | 0.69% |
Open: | $9.405 |
Close: | $9.49 |
High: | $9.6 |
Low: | $9.1601 |
Volume: | 24,531 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.49 | $9.405 | $9.49 | $9.6 | $9.1601 | 24,531 | 05-17-2024 |
$9.47 | $8.65 | $9.47 | $9.6732 | $8.65 | 45,935 | 05-16-2024 |
$8.85 | $8.59 | $8.85 | $9.12 | $8.42 | 18,417 | 05-15-2024 |
$8.43 | $8.22 | $8.43 | $8.43 | $7.71 | 17,251 | 05-14-2024 |
$8.12 | $8.51 | $8.12 | $9.03 | $7.4628 | 87,780 | 05-13-2024 |
$9.25 | $9.43 | $9.25 | $9.43 | $8.65 | 33,753 | 05-10-2024 |
$9.18 | $8.67 | $9.18 | $9.4639 | $8.6063 | 43,150 | 05-09-2024 |
$8.64 | $8.03 | $8.64 | $8.7615 | $8.03 | 15,602 | 05-08-2024 |
$8.15 | $8.21 | $8.15 | $8.28 | $8.01 | 11,355 | 05-07-2024 |
$8.32 | $9.1 | $8.32 | $9.8187 | $7.89 | 36,874 | 05-06-2024 |
$8.95 | $9.12 | $8.95 | $10.29 | $8.5453 | 78,427 | 05-03-2024 |
$8.8686 | $8.24 | $8.8686 | $9.46 | $8.1547 | 61,235 | 05-02-2024 |
$7.9 | $8.64 | $7.9 | $8.82 | $7.55 | 38,109 | 05-01-2024 |
$8.45 | $7.56 | $8.45 | $8.5 | $7.5201 | 84,957 | 04-30-2024 |
$7.43 | $6.9 | $7.43 | $7.55 | $6.9 | 26,954 | 04-29-2024 |
$6.9 | $7 | $6.9 | $7 | $6.71 | 19,769 | 04-26-2024 |
$6.94 | $6.61 | $6.94 | $7 | $6.47 | 28,704 | 04-25-2024 |
$6.72 | $6.96 | $6.72 | $7.13 | $6.48 | 66,355 | 04-24-2024 |
$6.86 | $6.57 | $6.86 | $7.04 | $6.57 | 26,465 | 04-23-2024 |
$6.72 | $7.14 | $6.72 | $7.35 | $6.49 | 129,458 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Benitec Biopharma Limited Company Name:
BNTC Stock Symbol:
NASDAQ Market:
2024-05-16 18:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD Subject was Safely Dosed with BB-301 in February- -Additional Interim Clinical Sa...
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace...